The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 25, 2022
Filed:
Feb. 28, 2017
Applicant:
Ose Immunotherapeutics, Nantes, FR;
Inventors:
Nicolas Poirier, Treillieres, FR;
Caroline Mary, Sainte-Pazanne, FR;
Assignee:
OSE IMMUNOTHERAPEUTICS, Nantes, FR;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/53 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/732 (2013.01); C07K 2317/94 (2013.01); C07K 2319/03 (2013.01);
Abstract
The description concerns humanized antibodies directed against the extracellular domain of the alpha chain of the receptor for interleukin-7 (IL-7), especially against the receptor for human IL-7 expressed on human cells (also designated human IL-7Ralpha or IL-7Ra or CD127) and which do not interfere with the IL-7 or TSLP signaling pathways. The antibodies described do not have an antagonistic effect on the IL-7 receptor, but may still present cytotoxic activity against CD127 positive cells. In a particular embodiment, the antibody does not have an agonist effect on the IL-7 receptor.